Deletion of PTPN2 in tumor cells increased IFN-γ signaling and antigen presentation to T cells, along with amplified growth arrest in response to cytokines, suggesting its therapeutic potential in potentiating immunotherapy efficacy [13]. The gene discussed is IFNG; the disease is neoplasm.